Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, highlights the need for trust between payers and providers, as well as finding balance in building consistent clinical pathways while prioritizing specific practice needs.
Collaboration between payers and providers is crucial for developing effective oncology care pathways, and at Tennessee Oncology and OneOncology, physician-led initiatives ensure legitimacy and consensus in decision-making, explained Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology.
Arrowsmith moderated the panel discussion, "Can Clinical Pathways Have Burnout, Too?" at Patient-Centered Oncology Care® (PCOC) 2023, and you can check out highlights from that panel here.
Transcript
How can payers and providers work together to develop pathways?
I think it's really critical for payers and providers to try to work together. It's difficult on both sides, there's not always 100% trust, and I think particularly on the provider side it's logistically difficult and not a 3-week process. Often it's a several years process, but working collaboratively is really critical. A huge problem that physicians have with payer-based pathways is that feeling that you're powerless and don't have say, and if you can work collaboratively, that can change from frustration to understanding that really makes things work better.
What is the oncologist’s role in building oncology care pathways at Tennessee Oncology and OneOncology?
Our pathways program at Tennessee Oncology and OneOncology is completely physician led, so it's using disease-based experts from across OneOncology to get together, review the latest data, and make changes to the pathways as appropriate. We have a support team of pharmacists that work with us as well, but it's really the individual physicians working together who come to the final decisions about the pathways. I always think it's super important to have that strong sense of legitimacy of the pathways that people feel "these are my pathways" rather than "these are decisions foisted upon me from some unknown people."
How do practices find the compromise between developing consistent pathways and prioritizing specific practice needs?
Increasingly thinking about the issues of where pathways specifically fit in, for a long time we've talked about guidelines like the [National Comprehensive Cancer Network] guidelines, and then pathways almost as a more specific subset of that. Pathways for us are 100% clinically driven, but increasingly, an individual practice or even an individual practice and an individual payer might have some agreement for in those situations when there's clinical equipoise. There are 2 treatments that either have been studied in a head-to-head fashion and found to be similar, or more frequently, when you have 2 drugs of the same class, say, 2 immune checkpoint inhibitors that have both been studied with chemotherapy, found to be superior to chemotherapy, and those studies look pretty similar. So the physician feels either one of those drugs is probably about the same, that maybe there might be a decision to use one or the other, perhaps in a value-based way, with a payer. In those settings, we don't really change the pathways, per se, but we're working on a variety of prompts to let that physician know at the point of care that really there's one of those that might be preferred in this particular patient at this particular time.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More